All News
Gout - Hot Topics in March 2023
A number of new reports this month shed new light on old issues in Gout.
Read Article
Atopic Disease Increases Osteoarthritis Risk
Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis.
Read Article
LAVLI - A New Autoinflammatory Disorder
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein).
Read Article
Docs' Liking for Knee Injection Tied to Industry Payments
MedPage Today
Physicians accepting payments from drug and device companies administered significantly more hyaluronic acid (HA) injections to Medicare beneficiaries for knee osteoarthritis, researchers found.
Read Article
Join RheumNow during the month of April as we discuss Women in Rheumatology, the XX Factor.
Sign up to attend our series!
https://t.co/m1E4WkK9Cx https://t.co/8RZNgoqzEI
Links:
Dr. John Cush RheumNow ( View Tweet)
386 pts w/ NPSLE (cerebritis); half (194) were Rx w/ intrathecal MTX+dexamethasone(iMTX); iMTX grp had higher SLEDAI (17 vs 14) & more pulse IV steroids (72% vs 50%). iMTX grp had better survival & NPSLE remission((P=0.042); best w/ ^CSF protein or SZ https://t.co/JsqUrYEwTK https://t.co/np6ntCR9xp
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 28,544 gout pts examined fracture risk based on achieving T2T w/ urate-lowering therapy (ULT). The 5 yr risk of hip Fx was 0.5% in those achieving target SU level, but was 0.8% for not achieving SUA target (HR 0.66; 95% CI: 0.46 to 0.93). https://t.co/Yw2zOS0g2v https://t.co/VkGSemlIE4
Links:
Dr. John Cush RheumNow ( View Tweet)
199 psoriasis Pts Rx w/ MTX monotherapy. Drug survival at 1, 2, & 5 yrs was 47, 36, & 29%; Avg MTX duration was 10.1 mos. Discontinuation mostly for AE (39.2%), ineffective (38.5%), PSO remission (12.2%). Durability best w/ ^age & dose >15 mg https://t.co/zKP0QCDzE2 https://t.co/35neGlhpE5
Links:
Dr. John Cush RheumNow ( View Tweet)
NHANES US population survey of 3101 adults (age 50yrs) wearing accelerometer in 2005 - looked at mortality in 2019. Compared to non-walkers (<8000 steps), mortality signif lower for walkers (> 8000 steps) 1-2 days/wk (−15%) or 3 - 7 days/wk (−16.5%) https://t.co/o8ved3gfsW https://t.co/pHAOYO6I2X
Links:
Dr. John Cush RheumNow ( View Tweet)
Triad of Trouble: A case of joint, skin and GI woes
Sara Faghihi Kashani, MD, presents her poster at RWCS 2023.
https://t.co/Y7YbgqbfzY https://t.co/EX1kTIiSRt
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/E74Qovuk0m https://t.co/vTAfWu0lta
Links:
Dr. John Cush RheumNow ( View Tweet)
"My eye is swollen": an underrecognized mimic of IgG4-related disease
Artem Minalyan, MD, presenting his poster at RWCS 2023.
https://t.co/9Dd8A9yry1 https://t.co/C0hgLV2r2W
Links:
Dr. John Cush RheumNow ( View Tweet)
Updated AAV Treatment Recommendations
AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
https://t.co/gQr92GpE5j https://t.co/SGDh1uNg2b
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 3804 runners from 2019, 2021 Chicago marathon looked at assocn betw marathons running and arthritis. Prevalence of hip / knee arthritis was 7.3%. Hip/Knee OA was assoc w/ prior injury/surgery, older age, FamHx, & BMI (not #marathons, mileage) https://t.co/P91dR9kSgY https://t.co/p7hFKEbGOw
Links:
Dr. John Cush RheumNow ( View Tweet)
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/RCtQnA9vc9 https://t.co/G5cXukkpUB
Links:
Dr. John Cush RheumNow ( View Tweet)
Anti-mesangial autoantibodies in IgA nephropathy
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney.
https://t.co/owOoAMrtxW https://t.co/RZMGkagcWJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/XKjuxLWAKH https://t.co/M7ri9AL2wH
Links:
Dr. John Cush RheumNow ( View Tweet)
What to do about pre-clinical RA?
Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi
Links:
Dr. John Cush RheumNow ( View Tweet)
Our old friend, hydroxychloroquine
Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus.
https://t.co/NJK7uJIqsV https://t.co/CQStRUUkUn
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/Ej0Rm2VFCk https://t.co/aiHGE1LsAr
Links:
Dr. John Cush RheumNow ( View Tweet)
